Suchergebnisse - "Personeni, Nicola"

PubPharm (7)

1

Cabozantinib for the treatment of hepatocellular carcinoma

enthalten in: Expert review of anticancer therapy | 2019

von Personeni, N. | Rimassa, L. | Pressiani, T. | +2

2

Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib

enthalten in: Future oncology (London, England) | 2019

von Personeni, N. | Pressiani, T. | Rimassa, L.

3

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

enthalten in: British journal of cancer | 2019

von Mazzaferro, V. | El-Rayes, B. | Droz Dit Busset, M. | +16

CommentIn: Lancet Oncol. 2019 Jan;20(1):e11. - PMID 30473470

4

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC) : a final analysis of a phase 3, randomised, placebo-controlled study

enthalten in: The Lancet. Oncology | 2018

von Rimassa, L. | Assenat, E. | Peck-Radosavljevic, M. | +27

CommentIn: Lancet Oncol. 2018 May;19(5):591-592. - PMID 29625880

5

Regorafenib for the treatment of unresectable hepatocellular carcinoma

enthalten in: Expert review of anticancer therapy | 2017

von Rimassa, L. | Pressiani, T. | Personeni, N. | +1

6

Tivantinib for second-line treatment of advanced hepatocellular carcinoma : a randomised, placebo-controlled phase 2 study

enthalten in: The Lancet. Oncology | 2013

von Santoro, A. | Rimassa, L. | Borbath, I. | +25

CommentIn: Lancet Oncol. 2013 Jan;14(1):7-8. - PMID 23182626

7

Outcome prediction to erlotinib in gastroesophageal adenocarcinomas : can we improve epidermal growth factor receptor and phospho-AKT testing?

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2007

von Personeni, N.

CommentOn: J Clin Oncol. 2006 Oct 20;24(30):4922-7. - PMID 17050876

1
[1]